Impaired clearance of phenacetin in hepatic cirrhosis and fibrosis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 1, 2007, Pages 55-62

  Qu, Z Q ^a   Li, X D ^b   Liu, H L ^c   He, Ping ^a   Wu, M C ^a  

^a EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CYP450 1A2; Liver function; Phenacetin

Indexed keywords

CARBOPLATIN; CYTOCHROME P450 1A2; EPIRUBICIN; FLUOROURACIL; IODINATED POPPYSEED OIL; PARACETAMOL; PARACETAMOL GLUCURONIDE; PARACETAMOL SULFATE; PHENACETIN; PHENACETIN O DEETHYLASE;

ADULT; ARTICLE; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

EID: 33847376979     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45055     Document Type: Article

References (28)

1. Abu-Qare AW, Elmasrye E, Abou-Donia MB. A role for P-glycoprotein in environmental toxicology. J Toxicol Environ Health Part B Crit Rev. 2003; 6: 279-288.
2. Barry M, Feely J. Enzyme induction and inhibition. Pharmacol Ther. 1990; 48: 71-94.
3. Burra P, Masier A. Dynamic tests to study liver function. Eur Rev Med Pharmacol Sci. 2004; 8: 19-21.
4. Cui ZF, He P, Luo M, Xia SQ, Wu MC. Phenacetin 0-deethylation in extrahepatic tissues of rats. Eur J Drug Metab Pharmacokinet. 2002; 27: 107-111.
5. Festi D, Capodicasa S, Vestito A, Mazzella G, Roda E, Vitacolonna E, Petrolati A, Angelico M, Colechia A. Breath tests with stable isotopes: have they role in liver transplantation? Eur Rev Med Pharmacol Sci. 2004; 8: 55-58.
6. Gao L, Ramzan I, Baker AB. Potential use of pharmacological markers to quantitatively assess during liver transplantation surgery. Ann Intens Care. 2000; 28: 375-385.
7. Groupe d'Étude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995; 332: 1256-1261.
8. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther. 1999; 256: 1189-1194.
9. He P, Cui ZF, Xia SQ, Luo M, Wang J, Zhang GQ, Zhao L, Li LF, Wu MC. An in vivo rat model for assessment of extrahepatic metabolism. J Pharmacol Toxicol Meth. 2001; 45: 181-185.
10. He P, Guo YJ, Wu MC. Clinical application of antipyrine clearance. Chin Pharmacol Bull. 1996; 12: 306-307.
11. International Hepatology Informatics Group. Diseases of the liver biliary tract. Standardization of nomenclature and diagnostic criteria and prognosis. Proceedings of the International Hepatology Informatics Group, Biennial Scientific Meeting, Sept 3-5, 1990. New York: Raven Press; 1994. pp. 47-164.
12. Jacob G, Michael M, Karen B, Geoffrey CF. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 1995; 21: 120-128.
13. Jorquera F, Almar M, Diaz-Golpe V, Olcoz JL, Garcia-Fernandez A, Gonzalez-Gallego J. Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy. Am J Gastroenterol. 2001; 96: 2456-2461.
14. Li XD, Xia SQ, Lv Y, He P, Han J, Wu MC. Conjugation metabolism of acetaminophen and bilirubin in extrahepatic tissues of rats. Life Sci. 2004; 74: 1307-1315.
15. Liu H, He P, Huang X Huo Li. Pharmacokinetic study of acetaminophen in patients with liver cirrhosis. Shanghai Med J. 2000; 23: 675-676.
16. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450 IIIA in patients with severe liver disease. Clin Pharmacol Ther. 1992; 51: 229-238.
17. Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-in-duced hepatotoxicity. Gastroenterology. 1997; 112: 1707-1709.
18. Nash RM, Stein L, Penno MB, Passananti GT, Vesell ES. Sources of interindividual variations in acetaminophen and antipyrine metabolism. Clin Pharmacol Ther. 1984; 36: 417-430.
19. Nelson DR, Koymans L, Kamatahi T. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6: 1-41.
20. Patterson LH, Murray GI. Tumor cytochrome P450 and drug activation. CurrPharm Res. 2002; 8: 1335-1347.
21. Prescott LF, Sansur M, Levin M, Conncy AH. The comparative metabolism of phenacetin and N-acetyl-p-aminophenol in man, with particular reference to effects on the kidney. Clin Pharmacol Ther. 1968; 9: 605-614.
22. Qu ZQ, Qian GJ, Chen H. Therapeutic effect of transcatheter arterial chemoembolization combined with percutaneous ethanol injection in hepatocellular carcinoma. Chinese-German J Clin Oncol. 2002; 1: 28-29.
23. Schneider PD. Preoperative assessment of liver function. Surg Clin North Am. 2004; 84: 355-373.
24. Self TH, Chafin CC, Soberman JE. Effect of disease states on theophylline serum concentrations: are we still vigilant? Am J Med Sci. 2000; 319: 177-182.
25. Sinha A, Muthiah K, Jiang W, Couroucli X, Barrios R, Moorthy B. Attenuation of hyperoxic lung injury by the CYP 1A inducer beta-naphthoflavone. Toxicol Sci. 2005; 87: 204-212.
26. Spina E, Perucca E. Newer and older antidepressants: a comparative review of drug interaction. CNS Drugs. 1994; 2: 479-497.
27. Vesell ES. The antipyrine test in clinical pharmacology: Conceptions and misconceptions. Clin Pharmacol Ther. 1979; 26: 275-286.
28. Xiao Dong L, Zhi Ping Z, Zhong Xiao W, Chong Shu C, Fattore C, Gatti G, D'Urso S, Perucc E. Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese. Br J Clin Pharmcol. 1999; 48: 638-640.